Manufacturing

Articles

Avantor plans to increase its single-use manufacturing footprint by 30% and double its cleanroom space in the US and Europe.

Avantor to Increase Global Capacity for Single-Use Technologies

Design for a new BMS multi-product cell therapy manufacturing site in Leiden is underway, with construction to start later in 2021.

Bristol Myers Squibb Plans Cell Therapy Manufacturing Site in the Netherlands

Catalent plans to add cryogenic capabilities to its facility in Philadelphia, which will strengthen its ability to cryogenically preserve cell therapies and other biological materials.

Catalent to Add Cryogenic Capabilities to Support Cell and Gene Therapy Development

The ATMPS and Ori Biotech collaboration aims to improve visibility and reporting of cell and gene therapy manufacturing through a pre-integrated data solution.

ATMPS and Ori Biotech Collaborate on Integrated Digital Platform for Cell and Gene Therapy

The UK's National Horizons Centre has been confirmed as a National Training Centre that will deliver on-site advanced therapies and vaccine manufacturing specific training.

National Horizons Centre to Provide ATMP and Vaccine Manufacture Training

Abecma is the first B-cell maturation antigen-directed chimeric antigen receptor T cell immunotherapy for the treatment of adult patients with relapsed or refractory multiple myeloma after four or more prior lines of therapy.

FDA Approves Bristol Myers Squibb and bluebird bio’s CAR T Cell Therapy for Refractory Multiple Myeloma

The companies will work together to determine the impact on autologous and allogeneic cell therapies by combining Kytopen’s proprietary Flowfect technology for non-viral cell engineering with other steps in the manufacturing process.

BioCentriq to Partner with Kytopen for Cell Therapy Manufacturing 

The companies will collaborate at BioCentriq’s GMP facilities to produce Tevogen’s proprietary COVID-19 targeted T cells.

Tevogen Bio and BioCentriq Team Up for COVID-19 T-Cell Therapy Manufacturing

Sana will be authorized to use the iPSC cell lines from FUJIFILM Cellular Dynamics for the research and development, clinical and commercial manufacture, and commercialization, of the cell therapies derived from the lines.

FUJIFILM Cellular Dynamics in Agreement with Sana Biotechnology to Develop iPSC-Derived Cell Therapies

This agreement enhances GSK’s investment in cell and gene therapy manufacturing in the UK for clinical trials.

Manufacturing, Cell Therapies